September 28, 2017
AbbVie Inc. and Amgen Inc. on Thursday announced a patent litigation settlement that will keep a biosimilar version of Humira, the world's best-selling drug, out of European pharmacies until 2018 and U.S. pharmacies until 2023.
August 05, 2016
AbbVie Inc. on Thursday told a Delaware federal court that Amgen Inc. has infringed 61 of its patents by attempting to get approval for a biosimilar of AbbVie's blockbuster immunosuppressant Humira and urged the court to block the copycat drug.